A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Erdafitinib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Janssen Pharmaceutical KK; Janssen Research & Development
- 30 Sep 2017 Results published in the Investigational New Drugs Journal.
- 20 May 2016 Status changed from recruiting to completed.
- 06 Apr 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History